Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veru Inc (VERU)
:VERU
Holding VERU?
Track your performance easily
VERU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.36 - $1.92
Previous CloseN/A
Volume1.22M
Average Volume (3M)1.85M
Market Cap
$123.50M
Enterprise Value$107.68M
Total Cash (Recent Filing)$3.28M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Feb 05, 2025EPS Estimate
-0.08Last Dividend Ex-Date
Apr 28, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding146,383,930
10 Day Avg. Volume2,454,796
30 Day Avg. Volume1,854,381
Standard Deviation0.39
R-Squared0.00501
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.31
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue6.38
Enterprise Value/Gross Profit18.39
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$4.33Price Target Upside341.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Veru News
PremiumCompany Announcements
Veru Inc. Sells FC2 Business to Focus on Biopharma
PremiumCompany Announcements
Veru Ends Sales Agreement with Jefferies, Halts Stock SalesPremiumEarning Releases
Veru Inc Reported Earnings. Did it Beat Estimates?
Ownership Overview
10.40% Insiders
6.36% Mutual Funds
0.34% Other Institutional Investors
72.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERU FAQ
What was Veru Inc’s price range in the past 12 months?
Veru Inc lowest stock price was $0.36 and its highest was $1.92 in the past 12 months.
What is Veru Inc’s market cap?
Veru Inc’s market cap is $123.50M.
When is Veru Inc’s upcoming earnings report date?
Veru Inc’s upcoming earnings report date is Feb 05, 2025 which is in 17 days.
How were Veru Inc’s earnings last quarter?
Veru Inc released its earnings results on Aug 08, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.058 by -$0.012.
Is Veru Inc overvalued?
According to Wall Street analysts Veru Inc’s price is currently Undervalued.
Does Veru Inc pay dividends?
Veru Inc pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru Inc dividends here
What is Veru Inc’s EPS estimate?
Veru Inc’s EPS estimate is -0.08.
How many shares outstanding does Veru Inc have?
Veru Inc has 146,383,930 shares outstanding.
What happened to Veru Inc’s price movement after its last earnings report?
Veru Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.058. Following the earnings report the stock price went up 5.195%.
Which hedge fund is a major shareholder of Veru Inc?
Currently, no hedge funds are holding shares in VERU
---
Veru Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (341.84% Upside)
$4.33 (341.84% Upside)
Blogger Sentiment
Bullish
VERU Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 222.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
123.62%
12-Months-Change
Fundamentals
Return on Equity
-145.40%
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Veru Inc
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
---
VERU Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of positive developments, such as significant progress in clinical trial enrollment and financial management, alongside ongoing challenges like declining prescription business revenue and sustained net losses. Despite these challenges, the overall momentum and strategic advancements suggest cautious optimism.Read More>---
VERU Stock 12 Month Forecast
Average Price Target
$4.33
▲(341.84% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Anavex Life Sciences
―
Immunic
―
Madrigal Pharmaceuticals
―
Geron
―
TG Therapeutics
―
Best Analysts Covering VERU
1 Year
1 Year Success Rate
13/32 ratings generated profit
1 Year Average Return
+14.11%
reiterated a buy rating 3 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 40.63% of your transactions generating a profit, with an average return of +14.11% per trade.
---